



Myomo, Inc. to Present at the 10th Annual LD Micro Main Event

CAMBRIDGE, Mass., November 28, 2017 – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will be presenting at the 10th annual LD Micro Main Event on Tuesday, December 5th at 9:30 AM PST / 12:30 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Chairman and Chief Executive Officer Paul R. Gudonis will be presenting, as well as meeting with investors.

A live audio webcast of the presentation will be available online at the [Investor Relations](#) page of the Company's website. An archive of the event will also be available for those unable to listen live.

The LD Micro Main Event is the largest independent conference for small/micro-cap companies and will feature 250 names presenting to an audience of over 1,000 attendees. In addition, there will be a variety of speakers/panelists discussing topics of interest to investors and issuers, along with coordinate evening events.

About Myomo

Myomo, Inc. is a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential conferences annually.

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.



Forward Looking Statements

This press release contains forward-looking statements regarding the Company's future business expectations, including the therapeutic benefit of the Company's products, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Our actual results could differ materially from those anticipated in these forward looking statements for many reasons, including, without limitation, risks related to regulatory approval and market acceptance of our products, and the other risk factors contained in our filings made with the Securities and Exchange Commission. More information about factors that potentially could affect Myomo's financial results is included in Myomo's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

For Myomo:

ir@myomo.com

Investor Relations:

Vivian Cervantes
PCG Advisory
[646-863-6274](tel:646-863-6274)
vivian@pcgadvisory.com

Public Relations:

Rachel Robbins
Greenough
[617-275-6521](tel:617-275-6521)
rrobbins@greenough.biz